We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO - Free Report) is a scientific instrument maker and a world leader in serving science. The company has three segments: Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics.
Analysts have slashed their earnings expectations across the board, landing the stock into an unfavorable Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Let’s take a closer look at how the company currently stacks up.
Thermo Fisher Scientific
It’s been a bumpy road for TMO shares year-to-date, down nearly 19% and unable to establish consistent strength. As we can see by the arrows circled below, shares have faced adverse recactions post-earnings in several instances throughout 2023.
Image Source: Zacks Investment Research
In its latest release, the company beat the Zacks Consensus EPS Estimate by 2% and posted a fractional revenue surprise. Earnings saw growth of 12% year-over-year, whereas revenue declined by roughly 1% from the year-ago period.
Image Source: Zacks Investment Research
In addition, Thermo Fisher lowered its FY23 guidance following the results, citing a challenging macroeconomic environment. The company now expects FY23 sales to be $42.7 billion and adjusted EPS of $21.50.
It’s worth noting that Thermo Fisher had already lowered FY23 guidance back in July, further reflected by share performance over the last several months.
The company has gone a long way in growing its dividend payout, carrying a sizable 16.5% five-year annualized dividend growth rate and reflecting its shareholder-friendly nature. TMO’s payout ratio sits at just 7% of its earnings.
Image Source: Zacks Investment Research
Bottom Line
Recent guidance cuts due to a challenging macroeconomic environment paint a challenging picture for the company’s shares in the near term.
Thermo Fisher Scientific (TMO - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bear of the Day: Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific (TMO - Free Report) is a scientific instrument maker and a world leader in serving science. The company has three segments: Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics.
Analysts have slashed their earnings expectations across the board, landing the stock into an unfavorable Zacks Rank #5 (Strong Sell).
Image Source: Zacks Investment Research
Let’s take a closer look at how the company currently stacks up.
Thermo Fisher Scientific
It’s been a bumpy road for TMO shares year-to-date, down nearly 19% and unable to establish consistent strength. As we can see by the arrows circled below, shares have faced adverse recactions post-earnings in several instances throughout 2023.
Image Source: Zacks Investment Research
In its latest release, the company beat the Zacks Consensus EPS Estimate by 2% and posted a fractional revenue surprise. Earnings saw growth of 12% year-over-year, whereas revenue declined by roughly 1% from the year-ago period.
Image Source: Zacks Investment Research
In addition, Thermo Fisher lowered its FY23 guidance following the results, citing a challenging macroeconomic environment. The company now expects FY23 sales to be $42.7 billion and adjusted EPS of $21.50.
It’s worth noting that Thermo Fisher had already lowered FY23 guidance back in July, further reflected by share performance over the last several months.
The company has gone a long way in growing its dividend payout, carrying a sizable 16.5% five-year annualized dividend growth rate and reflecting its shareholder-friendly nature. TMO’s payout ratio sits at just 7% of its earnings.
Image Source: Zacks Investment Research
Bottom Line
Recent guidance cuts due to a challenging macroeconomic environment paint a challenging picture for the company’s shares in the near term.
Thermo Fisher Scientific (TMO - Free Report) is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company’s earnings outlook.
For those seeking strong stocks, a great idea would be to focus on stocks carrying a Zacks Rank #1 (Strong Buy) or a Zacks Rank #2 (Buy) – these stocks sport a notably stronger earnings outlook paired with the potential to deliver explosive gains in the near term.